Detailed Narrative
Global Performance Overview
Mondelez reported 'quite good' Q2 results, characterized by effective pricing and better-than-expected bottom-line performance. The company highlighted a strong global balance, with robust performance in international markets offsetting continued weakness in North America. Chocolate pricing and revenue growth management (RGM) actions are progressing as anticipated, and the company is maintaining its full-year outlook.
Regional Dynamics
Europe demonstrated resilience with strong share gains, despite a heatwave in June and July that temporarily impacted chocolate volumes. North America faced a more challenging environment due to consumer anxiety, inflation concerns, and a soft biscuit category with declining volumes. Emerging markets, including Brazil, India, and Mexico, were a significant growth engine, delivering double-digit growth and strong share gains, despite some consumer confidence softness.
North America Strategy and Outlook
In North America, management does not anticipate a material category rebound for the remainder of the year, projecting biscuit category volumes to be down 3% in H2 FY25. To address this, the company is implementing incremental, surgical pricing actions, focusing on boosting productivity in H2, and expanding into alternate channels like club, dollar, and value stores where share gains are notable. Profitability and revenue are expected to improve in Q4 and H2, respectively.
Cocoa Market and Hedging
Cocoa market fundamentals are improving, with grinding numbers down 7-8% and pod counts in West Africa being promising. Cocoa butter prices have dramatically decreased compared to last year, offering a material benefit. While industry stock levels remain low, the overall sentiment suggests cocoa prices will eventually come down. The company took advantage of recent price drops and is contemplating hedging strategies for 2026, with potential for material upside if supply outpaces demand.
GLP-1 Impact Assessment
Mondelez conducted an in-depth analysis and found no real impact from GLP-1 drugs on its current volumes. The observed negative volume trends and shifts in consumer buying behavior are primarily attributed to economic factors. With GLP-1 penetration at about 4% of the adult population, an 11% calorie reduction, and an average 9-month usage duration, the overall effect on total calorie intake is estimated at a negligible 0.4%, and no significant increase in penetration is expected in 2026 or over the next decade.
Retailer Destocking
Retailer destocking in North America, which impacted Q2, was attributed to retailers managing cash flow, a general slowdown in consumption, and anticipation of tariffs. Retailers increased imports of certain items and offset this by reducing inventory in others. The company expects Q3 to be 'clean' regarding retailer inventory, and is shifting focus to alternate channels to mitigate the impact of destocking.